Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
41 hedge funds and large institutions have $9.95M invested in Viracta Therapeutics, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 13 closing their positions.
221% more call options, than puts
Call options by funds: $45K | Put options by funds: $14K
13% less funds holding
Funds holding: 47 → 41 (-6)
40% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 10
46% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 13
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
64% less capital invested
Capital invested by funds: $28M → $9.95M (-$18M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$105K |
| 2 |
Jane Street
New York
|
+$59.4K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$35.4K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$33.9K |
| 5 |
JP Morgan Chase
New York
|
+$15.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Caxton Corporation
Princeton,
New Jersey
|
-$3.38M |
| 2 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$2.46M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$1.79M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
-$1.55M |
| 5 |
CA
Corriente Advisors
Fort Worth,
Texas
|
-$1.25M |
VIRX Hedge Fund Activity: Q2 2020 in Review
41 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q2 2020, worth a combined $9.95M — down 64% from $28M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of VIRX and 7 opened new positions — a net loss of 6 holders — while 10 trimmed existing stakes and 6 added.
The largest buyer was Citadel Advisors, adding an estimated $105K. The largest seller was Caxton Corporation, exiting entirely with an estimated $3.38M sold.
- 41 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q2 2020, down from 47 in Q1 2020.
- Funds reported $9.95M of Viracta Therapeutics, Inc. Common Stock stock for Q2 2020, down 64% quarter-over-quarter.
- 7 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q2 2020 and 13 closed out, a net change of -6 holders.
- The largest Viracta Therapeutics, Inc. Common Stock buyer in Q2 2020 was Citadel Advisors, an estimated $105K added.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q2 2020 was Caxton Corporation, an estimated $3.38M sold.
Based on aggregated 13F filings for Q2 2020.